MilliporeSigma Announces Expansion of Biosafety Testing Laboratory in Singapore to Strengthen Services Across Asia Pacific

News Release

• Expansion adds first BioReliance^®Cell Line Characterization and GMP Next-Generation Sequencing in Asia Pacific
• Enhanced testing capabilities to deliver speed, sensitivity, and sustainability for biopharma customers in the region 
• Supports industry shift to molecular methods and animal-free testing

Burlington, MA, August 11, 2026 – MilliporeSigma, the U.S. and Canada Life Science business of  Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the expansion of its Singapore lab to further strengthen analytical and biosafety testing services for customers across the Asia Pacific region. Biosafety testing is a critical step in the drug development and manufacturing process, helping to ensure that biologics are safe, effective, and compliant with regulatory requirements. 

The expansion builds on the company’s global testing expertise of more than 75 years and marks a significant milestone in providing an advanced, local contract testing services portfolio for the region’s growing biopharma industry. 

“Localizing these BioReliance^® testing capabilities means our Asia Pacific biopharma customers can accelerate their development timelines, improve operational efficiency, and meet evolving regulatory and sustainability standards” said Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany. “This investment underscores the company’s commitment to empowering medicine makers by providing industry-leading analytical and biosafety testing services and technical expertise.”

Merck KGaA, Darmstadt, Germany's Singapore laboratory will become the first BioReliance^® facility in Asia-Pacific to offer both Cell Line Characterization services and GMP next-generation sequencing (NGS) capabilities. It will also offer advanced molecular methods including Blazar^®, a proprietary platform for rapid virus detection.

The expanded facility aims to support the industry’s move towards state-of-the-art quality control testing of biologics and 3Rs (Replacement, Reduction, and Refinement of animal use) through advanced molecular methods.

“The company’s expansion of the BioReliance^® lab will bring world-class and next-generation testing services to biopharmaceutical companies in Singapore and the region. We look forward to continuing our partnership with Merck KGaA, Darmstadt, Germany, to strengthen Singapore’s ecosystem, build new capabilities within our local workforce, and enable the delivery of innovative therapies to patients,” said Goh Wan Yee, Senior Vice President and Head of Healthcare, Singapore Economic Development Board.

The Singapore BioReliance^® lab was opened in 2018, and the expansion will bring the total lab area to over 1,000 square meters. This expansion is also a key step in the company’s broader strategy to support the region’s dynamic life science ecosystem and drive scientific progress.  

About the Life Science business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 27,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2025, Merck KGaA, Darmstadt, Germany, generated sales of € 21.1 billion in 65 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.  

Follow MilliporeSigma on X (formerly Twitter) @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.